Actualités et Activités de Agios Pharmaceuticals
Présence
Agios Pharmaceuticals appartient à Sagard Holdings. Sagard Holdings a une présence directe dans 4 pays.
Sagard Holdings a 12 filiales dont Acheel, Achieve et ADIT.
Elles sont en:
- Assurance23%
- Services financiers23%
- Autre54%
Dirigeants
Voir l'organigramme avec ses 16 principaux dirigeants
Biographies les plus recherchées chez Agios Pharmaceuticals
- Brian Goff, Chief Executive Officer and Director
- Jacqualyn Fouse, Chairman of the Board
- Maykin Ho, Director
Changements de dirigeants chez Agios Pharmaceuticals
- Krishnan Viswanadhan, a rejoint l'entreprise comme Chief Corporate Development & Strategy Officer (publié le 7 mars 2025).
- David Schenkein, Director, quittera l'entreprise le 28 févr. 2025 (publié le 14 février 2025).
Changements de dirigeants chez Sagard Holdings
- Parinaz Sobhani, a rejoint l'entreprise comme Head, Artificial Intelligence (publié le 30 août 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Agios Pharmaceuticals.
Pharmacie
Sagard Holdings a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Agios Pharmaceuticals
- Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 | Agios Pharmaceuticals, Inc.
- Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia | Agios Pharmaceuticals, Inc.
- Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients | Agios Pharmaceuticals, Inc.
- Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs | Agios Pharmaceuticals, Inc.
- Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 | Agios Pharmaceuticals, Inc.
- Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 | Agios Pharmaceuticals, Inc.
- Agios Reports Business Highlights and Second Quarter 2020 Financial Results | Agios Pharmaceuticals, Inc.
- Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020 | Agios Pharmaceuticals, Inc.
- Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 | Agios Pharmaceuticals, Inc.
- Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia | Agios Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Agios Pharmaceuticals
- Agios Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Agios Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
